Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg
Completed
AstraZeneca
Phase 3
2006-09-01
In this study it is intended to compare the blood pressure lowering effect of the combination
of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg and the
combination of candesartan 32 mg and HCT 12.5 mg to that of candesartan 32 mg alone in
patients whose blood pressure is not well controlled on candesartan 32 mg monotherapy. The
Primary Objectives are to compare sitting BP lowering effect of candesartan/HCT 32/25 mg and
candesartan/HCT 32/12.5 mg with that of candesartan 32 mg, respectively.
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
Completed
AstraZeneca
Phase 3
2007-01-01
The aim is to compare the blood pressure lowering effect of the combination of candesartan
cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32
mg alone, HCT 25 mg alone and placebo in hypertensive adults.
Candesartan Effect in Second Stage Arterial Hypertension
Completed
AstraZeneca
Phase 4
2008-02-01
To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either
candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
Completed
Takeda
Phase 4
2009-10-01
The purpose of this study is to see if Candesartan, once daily (QD), added with
Hydrochlorothiazide may be helpful in treating people with newly diagnosed severe essential
hypertension.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
